The effect of the platelet derived wound healing formula and the nerve growth factor on the experimentally injured spinal cord.
The main purpose of this study is to investigate the effect of platelet derived wound healing formula (PDWHF) and nerve growth factor (NGF) in the treatment of experimental spinal cord injury. PDWHF is a conglomerate of growth factors which include platelet derived growth factor (PDGF), platelet derived angiogenesis factor (PDAF), transforming growth factor-beta (TGF beta) and platelet factor IV (PF4). Complete spinal cord transection was performed at T12 in rats and the treatment of the spinal cord injury was achieved by filling the dead space with type 1 collagen gel impregnated with PDWHF, or with 2.5S-NGF. Controls were treated with only type 1 collagen gel. Animals were sacrificed at 1, 2 or 3 months. Histopathologically, tissue autolysis and cavity formation by phagocytosis expanded 1-3 mm into the cord stumps and the volume of cavitation was less in the two treated groups. In the NGF group, a greater number of surviving nerve cells were observed in this region. Most of the control animals formed only thin, short axonal bundles, however, increased axonal regrowth was noted in animals treated with trophic factors, especially in the NGF group. The NGF group formed thick axonal bundles and abundant neuroma. Increased angiogenesis was observed in the collagen gel matrix and the injured spinal cord parenchyma, in the PDWHF group. Recent studies have shown that mammalian adult CNS possesses the ability for structural and/or functional plasticity following injury under appropriate circumstances. In this in vivo study, exogenous NGF appeared to induce axomal outgrowth and nerve cell survival. PDWHF produced notable angiogenesis which seemed to improve the extracellular microenvironment. This may be important for the delivery of exogenous trophic factors, nutrients and for the changes of extracellular matrices to support nerve cells and axons.
Hiraizumi
Y
Y
Department of Orthopaedic Surgery, Showa University, Tokyo, Japan.
Fujimaki
E
E
Transfeldt
E E
EE
Kawahara
N
N
Fiegel
V D
VD
Knighton
D
D
Sung
J H
JH
D000818:Animals; D001369:Axons / Q000502:physiology / Q000648:ultrastructure; D002470:Cell Survival / Q000187:drug effects; D045424:Complex Mixtures; D005260:Female; D006133:Growth Substances / Q000627:therapeutic use*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D009416:Nerve Regeneration / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013116:Spinal Cord / Q000473:pathology; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000473:pathology; D014945:Wound Healing / Q000502:physiology*
C078881:CT-102 activated platelet supernatant; D045424:Complex Mixtures; D006133:Growth Substances; D009414:Nerve Growth Factors